行情

NTLA

NTLA

Intellia
NASDAQ

实时行情|Nasdaq Last Sale

14.63
-0.53
-3.50%
盘后: 14.70 +0.07 +0.48% 18:26 01/17 EST
开盘
15.30
昨收
15.16
最高
15.38
最低
14.61
成交量
68.70万
成交额
--
52周最高
19.00
52周最低
10.26
市值
7.15亿
市盈率(TTM)
-7.4510
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NTLA 新闻

  • 华盛早报 | 特朗普弹劾案审讯在即,苹果完成新iPhone研发
  • 华盛通.1小时前
  • 揭秘阿里的帝国式管理
  • 虎嗅APP.1小时前
  • 美参院即将开审特朗普弹劾案 审讯程序仍未决定
  • 中国新闻网.1小时前
  • 二十世纪福克斯电影公司不再姓福克斯
  • 中国新闻网.1小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

NTLA 简况

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
展开

Webull提供Intellia Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。